European Journal of Heart Failure · 2010 · 322 citations · 15 references
MedicineCardiologyPhysiologyCardiovascular GeneticsCritical Care CardiologyCardiovascular DiseaseCardiovascular Molecular PhysiologyHeart FailureOrgan FailureAcute Decompensated Heart Failure CareAcute Decompensated Heart Failure TreatmentCardiac SkeletonHeart Failure Molecular MechanismsHeart Failure PhysiologyHeart Failure ProgressionInpatient Mortality
AIMS: To determine the relationship between galectin-3 concentrations and cardiac structure in patients with acute dyspnoea, and to evaluate the impact of galectin-3 independent of echocardiographic measurements on long-term mortality. METHODS AND RESULTS: One hundred and fifteen patients presenting to the emergency department with acute dyspnoea who had galectin-3 levels and detailed echocardiographic studies on admission were studied. Galectin-3 levels were associated with older age (r = 0.26, P = 0.006), lower creatinine clearance (r = -0.42, P < 0.001), and higher levels of N-terminal-proBNP (r = 0.39, P < 0.001). Higher galectin-3 levels were associated with tissue Doppler E/E(a) ratio (r = 0.35, P = 0.01), a lower right ventricular (RV) fractional area change (r = -0.19, P = 0.05), higher RV systolic pressure (r = 0.37, P < 0.001), and more severe mitral (r = 0.30, P = 0.001) or tricuspid regurgitation (r = 0.26, P = 0.005). In patients diagnosed with heart failure (HF), the association between galectin-3 and valvular regurgitation and RV systolic pressure persisted. In a multivariate Cox regression model, galectin-3 remained a significant predictor of 4-year mortality independent of echocardiographic markers of risk. Dyspnoeic patients with HF and galectin-3 levels above the median value had a 63% mortality; patients less than the median value had a 37% mortality (P = 0.003). CONCLUSION: Among dyspnoeic patients with and without ADHF, galectin-3 concentrations are associated with echocardiographic markers of ventricular function. In patients with ADHF, a single admission galectin-3 level predicts mortality to 4 years, independent of echocardiographic markers of disease severity.
15
Impact of Aortic Stiffness on Survival in End-Stage Renal Disease
Jacques Blacher, Alain P. Guérin, Bruno Pannier et al. · Circulation · 1999 · 2.1K citations · Full text
Medicine, Cardiology, Nephrology +17
James L. Januzzi, Roland van Kimmenade, John G. Lainchbury et al. · European Heart Journal · 2005 · 1.2K citations · Full text
Cardiac Troponin and Outcome in Acute Heart Failure
W. Frank Peacock, Teresa De Marco, Gregg C. Fonarow et al. · New England Journal of Medicine · 2008 · 724 citations · Full text